The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Open accessAbstract
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and mutating continuously, giving rise to various variants with variable degrees of infectivity and lethality. The virus that initially appeared in China later mutated several times, wreaking havoc and claiming many lives worldwide amid the ongoing COVID-19 pandemic. After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies. Several theories are on the surface to explain how the Omicron has gathered such a high number of mutations within less time. Few of them are higher mutation rates within a subgroup of population and then its introduction to a larger population, long term persistence and evolution of the virus in immune-compromised patients, and epizootic infection in animals from humans, where under different immune pressures the virus mutated and then got reintroduced to humans. Multifaceted approach including rapid diagnosis, genome analysis of emerging variants, ramping up of vaccination drives and receiving booster doses, efficacy testing of vaccines and immunotherapies against newly emerged variants, updating the available vaccines, designing of multivalent vaccines able to generate hybrid immunity, up-gradation of medical facilities and strict implementation of adequate prevention and control measures need to be given high priority to handle the on-going SARS-CoV-2 pandemic successfully.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
Self-citationCele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00306-8 · Cited by 1,288
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,226
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881
Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02249-2 · Cited by 860
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 705
SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020
Oreshkova, N., Molenaar, R. J., Vreman, S., Harders, F., Oude Munnink, B. B., Hakze-van der Honing, R. W., Gerhards, N., Tolsma, P., Bouwstra, R., Sikkema, R. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.23.2001005 · Cited by 702
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P. J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 694
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C., Liu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04442-5 · Cited by 654
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein
Kumar, S., Thambiraja, T. S., Karuppanan, K., & Subramaniam, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27526 · Cited by 579
Heavily mutated Omicron variant puts scientists on alert
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-03552-w · Cited by 553
Tarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540
The origins of SARS-CoV-2: A critical review
Holmes, E. C., Goldstein, S. A., Rasmussen, A. L., Robertson, D. L., Crits-Christoph, A., Wertheim, J. O., Anthony, S. J., Barclay, W. S., Boni, M. F., Doherty, P. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.017 · Cited by 509
SARS‐CoV‐2 Omicron variant: Characteristics and prevention
He, X., Hong, W., Pan, X., Lu, G., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.110 · Cited by 506
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
Rössler, A., Riepler, L., Bante, D., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119236 · Cited by 466
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Dal Monego, S., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103154118 · Cited by 440
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432
Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n2713 · Cited by 421
Herrewegh, A. A. P. M., Smeenk, I., Horzinek, M. C., Rottier, P. J. M., & de Groot, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4508-4514.1998 · Cited by 419
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119358 · Cited by 418
Lu, L., Mok, B. W. Y., Chen, L. L., Chan, J. M. C., Tsang, O. T. Y., Lam, B. H. S., Chuang, V. W. M., Chu, A. W. H., Chan, W. M., Ip, J. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1041 · Cited by 407
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01700-x · Cited by 403
Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Malik, A. A., De la Cruz, E., Jorge, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01705-6 · Cited by 401
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
Zhang, L., Li, Q., Liang, Z., Li, T., Liu, S., Cui, Q., Nie, J., Wu, Q., Qu, X., Huang, W., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017757 · Cited by 357
Torjesen, I. (2021) · BMJ · doi:10.1136/bmj.n2943 · Cited by 348
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, E., Kronig, I., Neher, R. A., Eckerle, I., Vetter, P., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.022 · Cited by 345
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00915-3 · Cited by 341
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook, D., Stuart, D. I., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02844-0 · Cited by 339
Ai, J., Zhang, H., Zhang, Y., Lin, K., Zhang, Y., Wu, J., Wan, Y., Huang, Y., Song, J., Fu, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2022440 · Cited by 339
Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
Brandal, L. T., MacDonald, E., Veneti, L., Ravlo, T., Lange, H., Naseer, U., Feruglio, S., Bragstad, K., Hungnes, O., Ødeskaug, L. E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2101147 · Cited by 318
Saxena, S. K., Kumar, S., Ansari, S., Paweska, J. T., Maurya, V. K., Tripathi, A. K., & Abdel‐Moneim, A. S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27524 · Cited by 294
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant
Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., & Qian, W. (2021) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.12.003 · Cited by 288
Omicron variant and booster COVID-19 vaccines
Burki, T. K. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00559-2 · Cited by 285
How bad is Omicron? What scientists know so far
Callaway, E., & Ledford, H. (2021) · Nature · doi:10.1038/d41586-021-03614-z · Cited by 277
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance
Zhang, X., Wu, S., Wu, B., Yang, Q., Chen, A., Li, Y., Zhang, Y., Pan, T., Zhang, H., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00852-5 · Cited by 262
OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear
Thakur, V., & Ratho, R. K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27541 · Cited by 240
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa
Wang, L., & Cheng, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27516 · Cited by 230
Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor
Lupala, C. S., Ye, Y., Chen, H., Su, X.-D., & Liu, H. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.079 · Cited by 217
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Schmidt, F., Weisblum, Y., Rutkowska, M., Poston, D., DaSilva, J., Zhang, F., Bednarski, E., Cho, A., Schaefer-Babajew, D. J., Gaebler, C., et al. (2021) · Nature · doi:10.1038/s41586-021-04005-0 · Cited by 215
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
Kannan, S. R., Spratt, A. N., Sharma, K., Chand, H. S., Byrareddy, S. N., & Singh, K. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102779 · Cited by 215
Syed, A. M., Ciling, A., Taha, T. Y., Chen, I. P., Khalid, M. M., Sreekumar, B., Chen, P.-Y., Kumar, G. R., Suryawanshi, R., Silva, I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200592119 · Cited by 207
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!
Gao, S., Guo, H., & Luo, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27491 · Cited by 205
Ito, K., Piantham, C., & Nishiura, H. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27560 · Cited by 205
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
Hu, J., Peng, P., Cao, X., Wu, K., Chen, J., Wang, K., Tang, N., & Huang, A.-L. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00836-z · Cited by 204
Omicron variant genome evolution and phylogenetics
Kandeel, M., Mohamed, M. E. M., Abd El‐Lateef, H. M., Venugopala, K. N., & El‐Beltagi, H. S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27515 · Cited by 202
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe
Thakur, V., Bhola, S., Thakur, P., Patel, S. K. S., Kulshrestha, S., Ratho, R. K., & Kumar, P. (2022) · Infection · doi:10.1007/s15010-021-01734-2 · Cited by 195
Beyond Omicron: what’s next for COVID’s viral evolution
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-03619-8 · Cited by 190
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters
McMahan, K., Giffin, V., Tostanoski, L. H., Chung, B., Siamatu, M., Suthar, M. S., Halfmann, P., Kawaoka, Y., Piedra-Mora, C., Jain, N., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.004 · Cited by 190
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 188
Petersen, E., Ntoumi, F., Hui, D. S., Abubakar, A., Kramer, L. D., Obiero, C., Tambyah, P. A., Blumberg, L., Yapi, R., Al-Abri, S., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.040 · Cited by 187
Espenhain, L., Funk, T., Overvad, M., Edslev, S. M., Fonager, J., Ingham, A. C., Rasmussen, M., Madsen, S. L., Espersen, C. H., Sieber, R. N., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.50.2101146 · Cited by 180
Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021
Jansen, L., Tegomoh, B., Lange, K., Showalter, K., Figliomeni, J., Abdalhamid, B., Iwen, P. C., Fauver, J., Buss, B., & Donahue, M. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm705152e3 · Cited by 176
Gu, H., Krishnan, P., Ng, D. Y. M., Chang, L. D. J., Liu, G. Y. Z., Cheng, S. S. M., Hui, M. M. Y., Fan, M. C. Y., Wan, J. H. L., Lau, L. H. K., et al. (2022) · Emerging Infectious Diseases · doi:10.3201/eid2802.212422 · Cited by 175
Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions
Zhou, L., Ayeh, S. K., Chidambaram, V., & Karakousis, P. C. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06222-4 · Cited by 174
SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications
Sharun, K., Dhama, K., Pawde, A. M., Gortázar, C., Tiwari, R., Bonilla-Aldana, D. K., Rodriguez-Morales, A. J., de la Fuente, J., Michalak, I., & Attia, Y. A. (2021) · Veterinary Quarterly · doi:10.1080/01652176.2021.1921311 · Cited by 170
Self-citationThe new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant
Ali, F., Kasry, A., & Amin, M. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100086 · Cited by 163
Terada, Y., Matsui, N., Noguchi, K., Kuwata, R., Shimoda, H., Takehisa, S. O. M. A., Mochizuki, M., & Maeda, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106534 · Cited by 155
Where did ‘weird’ Omicron come from?
Kupferschmidt, K. (2021) · Science · doi:10.1126/science.acx9738 · Cited by 154 · cited 4×
“…with immune escape and the N501Y substitution associated with most VOC were reported, strengthening the hypothesis of intra-host evolution of VOCs (Kupferschmidt, 2021c). mRNA- and non-mRNA-based vaccines may have a role in generating Omicron variants in a chronically infected COVID-19 patient,…”
InfluentialHybrid immunity improves B cells and antibodies against SARS-CoV-2 variants
Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04117-7 · Cited by 151
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147
Emergence of Omicron third lineage BA.3 and its importance
Desingu, P. A., Nagarajan, K., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27601 · Cited by 145
Self-citationBartsch, Y. C., Tong, X., Kang, J., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Riquelme, A. J., Cai, Y., Renzi, I., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9243 · Cited by 145
Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant
Sun, Y., Lin, W., Dong, W., & Xu, J. (2021) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2021.12.001 · Cited by 133
Omicron likely to weaken COVID vaccine protection
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-03672-3 · Cited by 132
Wang, X., Zhao, X., Song, J., Wu, J., Zhu, Y., Li, M., Cui, Y., Chen, Y., Yang, L., Liu, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2030200 · Cited by 131
Molnupiravir: A new candidate for COVID‐19 treatment
Pourkarim, F., Pourtaghi‐Anvarian, S., & Rezaee, H. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.909 · Cited by 130
How severe are Omicron infections?
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-03794-8 · Cited by 127
High Rate of Asymptomatic Carriage Associated with Variant Strain OmicronPreprint
Garrett, N., Tapley, A., Andriesen, J. G., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C. L., Randhawa, A. K., Ketter, N., et al. (2021) · medRxiv · doi:10.1101/2021.12.20.21268130 · Cited by 125
Omicron SARS-CoV-2 variant: What we know and what we don’t
Ferré, V. M., Peiffer‐Smadja, N., Visseaux, B., Descamps, D., Ghosn, J., & Charpentier, C. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100998 · Cited by 121
Sharun, K., Tiwari, R., Natesan, S., & Dhama, K. (2020) · Veterinary Quarterly · doi:10.1080/01652176.2020.1867776 · Cited by 115
Self-citationPersistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infectionPreprint
Karim, F., Moosa, M.-Y. S., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, J., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21258228 · Cited by 115
Pascarella, S., Ciccozzi, M., Zella, D., Bianchi, M., Benedetti, F., Benvenuto, D., Broccolo, F., Cauda, R., Caruso, A., Angeletti, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27210 · Cited by 113
Covid-19: Early studies give hope omicron is milder than other variants
Christie, B. (2021) · BMJ · doi:10.1136/bmj.n3144 · Cited by 113
Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prahl, M., Gaw, S. L., Arunachalam, P. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7842 · Cited by 111
The Emergence of Omicron: Challenging Times Are Here Again!
Singhal, T. (2022) · The Indian Journal of Pediatrics · doi:10.1007/s12098-022-04077-4 · Cited by 109
Poudel, S., Ishak, A., Pérez-Fernández, J., Garcia, E., León‐Figueroa, D. A., Romaní, L., Bonilla‐Aldana, D. K., & Rodriguez-Morales, A. J. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102234 · Cited by 107
T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
Choi, S. J., Kim, D.-U., Noh, J. Y., Kim, S., Park, S., Jeong, H. W., & Shin, E. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00838-5 · Cited by 104
Dyer, O. (2021) · BMJ · doi:10.1136/bmj.n3104 · Cited by 102
Shrestha, N. K. M., Burke, P. C., Nowacki, A. S., Terpeluk, P., & Gordon, S. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac022 · Cited by 101
Yu, X., Wei, D., Xu, W., Li, Y., Li, X., Zhang, X., Qu, J., Yang, Z., & Chen, E. (2022) · Cell Discovery · doi:10.1038/s41421-022-00375-5 · Cited by 97
Parums, D. V. (2022) · Medical Science Monitor · doi:10.12659/msm.935952 · Cited by 94
Redd, A. D., Nardin, A., Kared, H., Bloch, E. M., Abel, B., Pekosz, A. S., Laeyendecker, O. B., Fehlings, M., Quinn, T. C., & Tobian, A. A. R. (2022) · mBio · doi:10.1128/mbio.03617-21 · Cited by 94
Omicron (B.1.1.529 variant of SARS‐CoV‐2); an emerging threat: Current global scenario
Mohapatra, R. K., Sarangi, A. K., Kandi, V., Azam, M., Tiwari, R., & Dhama, K. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27561 · Cited by 93
Self-citationRiediker, M., Briceño-Ayala, L., Ichihara, G., Albani, D., Poffet, D., Tsai, D.-H., Iff, S., & Monn, C. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30133 · Cited by 93
The puzzling mutational landscape of the SARS‐2‐variant Omicron
Fantini, J., Yahi, N., Colson, P., Chahinian, H., Scola, B. L., & Raoult, D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27577 · Cited by 91
Rabaan, A. A., Al-Ahmed, S. H., Garout, M. A., Al‐Qaaneh, A. M., Sule, A. A., Tirupathi, R., Mutair, A. S. A., Alhumaid, S., Hasan, A., Dhawan, M. K., et al. (2021) · Pathogens · doi:10.3390/pathogens10050565 · Cited by 89
Self-citationAhmed, S. F., Quadeer, A. A., & McKay, M. R. (2022) · Viruses · doi:10.3390/v14010079 · Cited by 89
Leary, S., Gaudieri, S., Parker, M. D., Chopra, A., JAMES, I. R., Pakala, S., Alves, E., John, M., Lindsey, B. B., Keeley, A. J., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i2.460 · Cited by 88
Li, X., Lester, D. R., Rosengarten, G., Aboltins, C. A., Patel, M. J., & Cole, I. S. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.152592 · Cited by 87
Khan, N. A., Al-Thani, H. A. S., & El-Menyar, A. A. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102246 · Cited by 87
Falcone, M., Tiseo, G., Valoriani, B., Barbieri, C., Occhineri, S., Mazzetti, P., Vatteroni, M. L., Suardi, L., Riccardi, N., Pistello, M., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00525-4 · Cited by 86
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 86
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Lee, C., Hsieh, C., & Ko, W. (2021) · Antibiotics · doi:10.3390/antibiotics10111294 · Cited by 86
Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
Banoun, H. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000515417 · Cited by 85
Vaughan, A. (2021) · The New Scientist · doi:10.1016/s0262-4079(21)02140-0 · Cited by 85
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Nie, C., Sahoo, A. K., Netz, R. R., Herrmann, A., Ballauff, M., & Haag, R. (2022) · ChemBioChem · doi:10.1002/cbic.202100681 · Cited by 85
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100527 · Cited by 81
Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater
Ahmed, W., Bivins, A. W., Smith, W. J. M., Metcalfe, S., Stephens, M., Jennison, A. V., Moore, F. A. J., Bourke, J., Schlebusch, S., McMahon, J., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153171 · Cited by 80
Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load
Quarleri, J. F., Galván, V., & Delpino, M. V. (2021) · GeroScience · doi:10.1007/s11357-021-00500-4 · Cited by 79
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistancePreprint
Chen, J., Wang, R., Gilby, N. B., & Wei, G. (2021) · PubMed · doi:10.48550/arxiv.2112.01318 · Cited by 78
Deerain, J. M., Druce, J. D., Tran, T., Batty, M., Yoga, Y., Fennell, M., Dwyer, D. E., Kok, J., & Williamson, D. A. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02479-21 · Cited by 78
Mourier, T., Shuaib, M., Hala, S. M., Mfarrej, S., Alofi, F. S., Naeem, R., Alsomali, A., Jorgensen, D., Subudhi, A. K., Ben-Rached, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28287-8 · Cited by 78
Domingo, E., & Perales, C. (2018) · European Biophysics Journal · doi:10.1007/s00249-018-1282-6 · Cited by 77
Daria, S., Bhuiyan, M. A., & Islam, M. R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27503 · Cited by 77
Omicron’s feeble attack on the lungs could make it less dangerous
Kozlov, M. (2022) · Nature · doi:10.1038/d41586-022-00007-8 · Cited by 76
SARS-CoV-2 reinfection and implications for vaccine development
Nainu, F., Abidin, R. S., Bahar, M. A., Frediansyah, A., Emran, T. B., Rabaan, A. A., Dhama, K., & Harapan, H. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1830683 · Cited by 75
Self-citationMahase, E. (2021) · BMJ · doi:10.1136/bmj.n3151 · Cited by 75
Wong, S., Au, A. K.-W., Chen, H., Yuen, L. L.-H., Li, X., Lung, D. C., Chu, A. W., Ip, J. D., Chan, W.-M., Tsoi, H., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100360 · Cited by 75
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 74
Resende, P. C., Delatorre, E. O., Gräf, T., Mir, D., Motta, F. C., Appolinario, L., Paixão, A. C. D., Mendonça, A. C. D. F., Ogrzewalska, M., Caetano, B. C., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.615280 · Cited by 73
PCR performance in the SARS-CoV-2 Omicron variant of concern?
Metzger, C., Lienhard, R., Seth-Smith, H. M. B., Roloff, T. C., Wegner, F., Sieber, J., Bel, M., Greub, G., & Egli, A. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30120 · Cited by 73
Mutational and phylogenetic analyses of the two lineages of the Omicron variant
Majumdar, S., & Sarkar, R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27558 · Cited by 72
The omicron variant of SARS‐CoV‐2: Understanding the known and living with unknowns
Ingraham, N. E., & Ingbar, D. H. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.685 · Cited by 71
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 70
Zeng, C., Evans, J. P., Chakravarthy, K. B., Qu, P.-K., Reisinger, S., Song, N.-J., Rubinstein, M., Shields, P., Li, Z.-H., & Liu, S.-L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.014 · Cited by 69
The mysterious origins of the Omicron variant of SARS-CoV-2
Du, P., Gao, G. F., & Wang, Q. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100206 · Cited by 69
Pascarella, S., Ciccozzi, M., Bianchi, M., Benvenuto, D., Cauda, R., & Cassone, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27528 · Cited by 68
A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals
Chavda, V. P., Feehan, J., & Apostolopoulos, V. (2021) · Vaccines · doi:10.3390/vaccines9060631 · Cited by 60
Mohiuddin, M., & Kasahara, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106716 · Cited by 60
Zooanthroponotic potential of SARS-CoV-2 and implications of reintroduction into human populations
Banerjee, A., Mossman, K. L., & Baker, M. L. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.004 · Cited by 53
Laurie, M. T., Liu, J., Sunshine, S., Peng, J., Black, D., Mitchell, A. M., Mann, S. A., Pilarowski, G. O. W., Zorn, K. C., Rubio, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab635 · Cited by 49
SARS-CoV-2 existence in sewage and wastewater: A global public health concern?
Dhama, K., Patel, S. K., Yatoo, M. I., Tiwari, R., Sharun, K., Dhama, J., Natesan, S. K. A., Malik, Y. S., Singh, K. P., & Harapan, H. (2020) · Journal of Environmental Management · doi:10.1016/j.jenvman.2020.111825 · Cited by 46
Self-citationOmicron-variant border bans ignore the evidence, say scientists
Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-03608-x · Cited by 46
Omicron: Call for updated vaccines
Li, X. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27530 · Cited by 46
Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt
Dhawan, M. K., Priyanka, & Choudhary, O. P. (2021) · International Journal of Surgery · doi:10.1016/j.ijsu.2021.106198 · Cited by 45
SARS-CoV-2 and Variant Diagnostic Testing Approaches in the United States
Thomas, E., Delabat, S., Carattini, Y., & Andrews, D. M. (2021) · Viruses · doi:10.3390/v13122492 · Cited by 45
Sohan, M., Hossain, M. J., & Islam, M. R. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27574 · Cited by 45
Lippi, G., Adeli, K., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1287 · Cited by 43
Covid-19: Omicron and the need for boosters
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n3079 · Cited by 40
Sharun, K., Tiwari, R., Saied, A. A., & Dhama, K. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.053 · Cited by 37
Self-citationFaustini, S. E., Shields, A. M., Banham, G. D., Wall, N. A., Al‐Taei, S., Tanner, C., Ahmed, Z., Efstathiou, E., Townsend, N., Goodall, M. D., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.002 · Cited by 37
SARS-CoV-2 Variants Detection Using TaqMan SARS-CoV-2 Mutation Panel Molecular Genotyping Assays
Neopane, P., Nypaver, J., Shrestha, R., & Beqaj, S. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s335583 · Cited by 36
Li, T., Maier, A., Carter, M., & Guan, T. H. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27562 · Cited by 36
Insights on the mutational landscape of the SARS-CoV-2 Omicron variantPreprint
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471499 · Cited by 35
Kazybay, B., Ahmad, A., Mu, C., Mengdesh, D., & Xie, Y. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102242 · Cited by 35
SARS‐CoV‐2 omicron variant: Could it be another threat?
Shanmugaraj, B., Malla, A., Khorattanakulchai, N., & Phoolcharoen, W. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27532 · Cited by 34
Omicron: a drug developer’s perspective
Fang, F., & Shi, P. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2023330 · Cited by 33
Omicron overpowers key COVID antibody treatments in early tests
Kozlov, M. (2021) · Nature · doi:10.1038/d41586-021-03829-0 · Cited by 33
Korath, A. D. J., Janda, J., Untersmayr, E., Sokołowska, M., Feleszko, W., Agache, I. O., Seida, A. A., Hartmann, K., Jensen‐Jarolim, E., & Pali‐Schöll, I. (2021) · Allergy · doi:10.1111/all.14991 · Cited by 32
Chan, M. (2022) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2022v4n1p50-54 · Cited by 32
Acceptance of a vaccine against COVID-19 – a systematic review of surveys conducted worldwide
Snehota, M., Vlčková, J., Čížková, K., Vachutka, J., Kolarova, H., Klaskova, E., & Kollárová, H. (2021) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2021_086 · Cited by 31
Fu, J. Y. L., Chong, Y. M., Sam, I., & Chan, Y. F. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114462 · Cited by 31
May, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 30
Shan, K.-J., Wei, C., Wang, Y., Huan, Q., & Qian, W. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100159 · Cited by 29
Wahid, M., Jawed, A., Mandal, R. K., Dailah, H. G., Janahi, E. M. A., Dhama, K., Somvanshi, P., & Haque, S. (2021) · PubMed · doi:10.26355/eurrev_202109_26805 · Cited by 28
Self-citationSARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
Blasi, F., Gramegna, A., Sotgiu, G., Saderi, L., Voza, A., Aliberti, S., & Amati, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106355 · Cited by 27
Lubin, J. H., Markosian, C., Balamurugan, D., Ma, M. T., Chen, C.-H., Liu, D., Pasqualini, R., Arap, W., Burley, S. K., & Khare, S. D. (2023) · JCI Insight · doi:10.1172/jci.insight.168296 · Cited by 26
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 26
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
Chen, Z., Zhang, P., Matsuoka, Y., Tsybovsky, Y., West, K. A., Santos, C. P., Boyd, L. F., Nguyen, H., Pomerenke, A., Stephens, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111528 · Cited by 26
‘Killer’ immune cells still recognize Omicron variant
Ledford, H. K. (2022) · Nature · doi:10.1038/d41586-022-00063-0 · Cited by 24
Omicron (B.1.1.529) variant: Development, dissemination, and dominance
Rahmani, S., & Rezaei, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27563 · Cited by 22
Furió, V., Garijo, R., Pinazo-Duran, M. D., Moyá, A., Bell, J. C., & Sanjuán, R. (2012) · Journal of Virology · doi:10.1128/jvi.00755-12 · Cited by 21
The race between vaccination and evolution of COVID-19 variants
Burki, T. K. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00443-4 · Cited by 18
Kibler, K. V., Szczerba, M., Lake, D. F., Roeder, A. J., Rahman, M. M., Hogue, B. G., Wong, L.-Y. R., Perlman, S. M., Li, Y., & Jacobs, B. L. (2022) · Vaccines · doi:10.3390/vaccines10081172 · Cited by 17
Comparative Studies of RNA Virus Evolution
Holmes, E. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374153-0.00005-9 · Cited by 16
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
Zou, H., Yang, Y., Dai, H., Xiong, Y., Wang, J., Lin, L., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732403 · Cited by 16
Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19)
Persad, G., Peek, M. E., & Shah, S. K. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1039 · Cited by 16
Vandeputte, J., Damme, P. V., Neyts, J. H., Audonnet, J.-C., Baay, M. F. D., & Neels, P. (2021) · Biologicals · doi:10.1016/j.biologicals.2021.08.001 · Cited by 14
Gelanew, T., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Teferi, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10060859 · Cited by 14
Maruki, T., Iwamoto, N., Kanda, K., Okumura, N., Yamada, G., Ishikane, M., Ujiie, M., Saito, M., Fujimoto, T., Kageyama, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1072 · Cited by 12
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
Golnabi, E. Y., Sanders, J. M., Johns, M. L., Lin, K., Ortwine, J. K., Wei, W., Mang, N. S., & Cutrell, J. B. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00769-8 · Cited by 7
Yaesoubi, R., You, S., Xi, Q., Menzies, N. A., Tuite, A. R., Grad, Y. H., & Salomon, J. A. (2021) · medRxiv · doi:10.1101/2021.12.13.21267657 · Cited by 7
Sexton, M. E., Waggoner, J. J., Carmola, L. R., Nguyen, P.-V., Wang, E. B., Khosravi, D., Taz, A., Arthur, R. A., Patel, M., Edara, V. V., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac032 · Cited by 7
The threat of the spread of SARS-CoV-2 variants in animals
Bonilla‐Aldana, D. K., & Rodriguez-Morales, A. J. (2021) · Veterinary Quarterly · doi:10.1080/01652176.2021.2008046 · Cited by 6
Penner, R. (2021) · Vaccines · doi:10.3390/vaccines9121509 · Cited by 5
Leshem, E., Gonen, T., Hoffman, T., Barsisat, A., Kreiss, Y., & Regev‐Yochay, G. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac003 · Cited by 5
Cited by
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 313
Self-citationPost-Vaccination Neutralization Responses to Omicron Sub-Variants
Jacobsen, H., Katzmarzyk, M., Higdon, M. M., Jiménez, V. C., Sitaras, I., Bar-Zeev, N., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10101757 · Cited by 21
Metadata
- Authors
- Khandia, R., Singhal, S., Alqahtani, T., Kamal, M. A., El-Shall, N. A., Nainu, F., Desingu, P. A., & Dhama, K.
- Venue
- Environmental Research
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 209
- Pages
- 112816
- ISSN
- 0013-9351 (ISSN-L)
- OpenAlex
- W4210338331
- Cited by
- 300
- References
- 180
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.